Joshua Cohen, Contributor

Disparities in lung cancer treatment may point to an access problem. Less than 62% of lung cancer patients in the U.S. receive treatments recommended by the National Comprehensive Cancer Network (NCCN) guidelines.

What the U.S. may target is a dismantling, or watering down, of restrictions with respect to NHS price setting and reimbursement of pharmaceuticals and medical devices.

While list prices have increased substantially over time, rebates have kept net spending growth by pharmacy benefit managers and payers in check. But, the rebates have generally not been passed through to patients, whose co-payments are often calculate…

The U.S. spends about twice as much on healthcare as other Organization for Economic Cooperation and Development (OECD) countries, but ranks near the bottom in terms of life expectancy, and that gap has widened sharply in recent years.

From a policy perspective, the ACA can continue – and has since January 2018 – without the mandate requiring that everyone have health insurance. But, to the courts policy doesn’t matter, it’s the intricate details of constitutionality and separability…

On the whole, however, PDPRA’s impact on the pharmaceutical industry is not nearly as potentially significant and punitive in terms of price controls as H.R. 3 would be if it became law.

policymakers must do more to construct patient-centric measures of the benefits conferred by medical technologies, and permit the patient’s voice to be heard more incisively, both on the input side regarding value assessment, and decision-making side.

Within a disease area the QALY is an indispensable measure of comparative benefit. And, in fact, across disease areas with similar sets of impacts and considerations, the QALY is invaluable. It’s when the QALY is used in certain inter-disease compariso…